CEO / President
Craig Baxter has over 30 years of experience in the pharmaceutical industry, and acquired an interest in Methapharm in 2015. He has extensive experience in the development of global sales and marketing organizations, as well as manufacturing facilities, in both finished dosage pharmaceuticals and API’s. He has held numerous senior executive positions including Chief Executive officer of Sherfam Inc, Apotex Holdings, Apotex International and Chairman of the Board of Cangene Corporation. In a charitable capacity, he served as a Director and Chairman of the Board for Humber River Hospital.
Founder / Director
Luciano’s involvement in the pharmaceutical industry began in Europe in the late sixties. Luciano founded Methapharm in 1996. He is a founding member of the GPIA (Generic Pharmaceutical Industry Association) in the USA and continues to serve on the Board of Directors for the organization, which is now called the Generic Pharmaceutical Association (GPhA). Formerly, Luciano served as Chairman of the CDMA (Canadian Drug Manufacturers’ Association) for over three years and was also a member of the SAGIT (Sectoral Advisory Group on International Trade Canada) for two years.
Executive Vice President / CLO
Chris Calenti is a licensed attorney and holds a B.Comm, a JD, and an MBA from the University of Toronto. With twenty years of commercial experience in specialty pharmaceuticals and active pharmaceutical ingredients, Chris is presently responsible for business development and licensing opportunities. He also serves as General Counsel to the corporate group of companies.
Director of Sales, Specialty Pharma
Sharron Brownlee has been Methapharm’s Director of Specialty Sales since 2016. She has 20 years of experience in Sales, Business Development, and Market Analysis. Sharron obtained a B.Sc. from the University of Guelph, a Degree in Marketing & Sales Management from the University of British Columbia, and a Master’s in International Relations from the University of Liverpool. Previously, she held Manager and Director roles in Market Access, Business Development and Sales & Marketing. In 2020, Sharron completed a certification program with Harvard Business School in Finance, Economics and Business Analytics.
Director of Respiratory
Carolina Azcona joined Methapharm as Director, Scientific and Medical Affairs in 2019 and transitioned in 2020 to lead the commercial Respiratory portfolio globally. Carolina has 16 years experience in clinical and commercial diagnostic genetic services. She obtained a BSc in Biological Sciences, MSc in Genetic Counselling from the University of British Columbia and an EMBA from Queen’s University. Carolina’s career history includes Director roles in Business Unit Management and Business Development at LifeLabs Medical Laboratory Services as well as Patient Management at University Health Network.
Jody Zimon Galerne
Director, Business Relations & Supply Chain
Jody Zimon Galerne holds a BA from the University of Western Ontario and has been with Methapharm since 2002. Jody assumed the role as Director, Business Relations and Supply Chain in 2019 and is responsible for developing and cultivating relationships with Business Partners as well as overseeing RFP submissions, production planning, and inventory management.
Director of Scientific Affairs
Bernice joined Methapharm in 2021 as the Director of Scientific Affairs. Bernice holds a Bachelor of Science in Chemistry and Microbiology from the University of Witwatersrand and has over 20 years of experience managing global regulatory teams for major pharmaceutical companies.
Dr. Bernard Ogbiti
Manager of Medical Affairs
Dr. Bernard Ogbiti joined Methapharm in 2021 as Manager of Medical Affairs. He has extensive experience in Pharmacovigilance and Medical Information and has held several clinical and medical research roles within the healthcare industry. Bernard is a published author and holds an MD from the Medical University of Lodz in Poland, as well as a BSc in Neuroscience from the University of Toronto. In 2020, Bernard completed a certification program with Harvard in Prescription Drug regulation, Cost and Access.